CoSyne Therapeutics Limited
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
CoSyne Therapeutics Limited - overview
Location
London, -, UK
Primary Industry
Biotechnology
About
Based in London, UK, and founded in 2021 by co-founders Louwai Muhammed, Liisi Laaniste, and Michael Johnson, CoSyne Therapeutics offers an artificial intelligence (AI) platform that uses a vast dataset to discover drugs tailored to an individual patient's specific genetics. CoSyne Therapeutics offers a drug discovery platform with features that combine a large dataset of genetic information with custom-built AI models. These models can analyze various biological and chemical factors to understand the complexities of brain diseases at a deeper level. By analyzing a patient's specific genetic data, CoSyne's AI can identify potential drug targets that address the root cause of their disease.
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.